SciVision Biotech Inc. (TPE:1786)
Taiwan · Delayed Price · Currency is TWD 48.50
-0.60 (-1.22%)
Jul 30, 2026, 1:30 PM CST
SciVision Biotech Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,674 | 5,241 | 7,466 | 5,254 | 3,587 | 3,283 | |
Market Cap Growth | -56.50% | -29.80% | 42.10% | 46.46% | 9.27% | -12.78% |
Enterprise Value | 3,243 | 4,767 | 6,908 | 4,936 | 3,075 | 3,197 |
Last Close Price | 49.10 | 70.30 | 97.27 | 71.05 | 48.60 | 42.90 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 28.66 | 32.28 | 30.82 | 29.54 | 25.32 | 32.28 |
Forward PE | - | 19.12 | 16.10 | 20.85 | 20.85 | 20.85 |
PS Ratio | 4.14 | 5.91 | 8.45 | 7.37 | 6.44 | 6.49 |
PB Ratio | 1.98 | 2.65 | 3.94 | 3.23 | 2.37 | 2.26 |
P/TBV Ratio | 1.98 | 2.65 | 3.94 | 3.24 | 2.38 | 2.27 |
P/FCF Ratio | - | 233.32 | 31.76 | 20.42 | 21.48 | 45.14 |
P/OCF Ratio | 64.15 | 42.27 | 27.67 | 19.32 | 19.71 | 33.33 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.65 | 5.38 | 7.82 | 6.92 | 5.52 | 6.32 |
EV/EBITDA Ratio | 13.81 | 18.33 | 22.27 | 18.88 | 15.74 | 18.47 |
EV/EBIT Ratio | 21.53 | 25.10 | 27.84 | 24.72 | 22.85 | 26.22 |
EV/FCF Ratio | - | 212.22 | 29.38 | 19.18 | 18.41 | 43.95 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.26 | 0.25 | 0.12 | 0.21 | 0.27 | 0.44 |
Debt / EBITDA Ratio | 2.06 | 1.79 | 0.72 | 1.32 | 2.10 | 3.62 |
Debt / FCF Ratio | - | 21.60 | 0.95 | 1.35 | 2.47 | 8.70 |
Net Debt / Equity Ratio | -0.23 | -0.22 | -0.31 | -0.24 | -0.14 | -0.04 |
Net Debt / EBITDA Ratio | -1.93 | -1.69 | -1.87 | -1.52 | -1.05 | -0.36 |
Net Debt / FCF Ratio | 12.82 | -19.61 | -2.47 | -1.54 | -1.23 | -0.86 |
Asset Turnover | 0.34 | 0.35 | 0.39 | 0.34 | 0.26 | 0.24 |
Inventory Turnover | 2.88 | 3.22 | 2.86 | 2.19 | 2.08 | 2.54 |
Quick Ratio | 3.23 | 6.70 | 2.91 | 5.80 | 5.54 | 1.82 |
Current Ratio | 4.09 | 8.17 | 3.46 | 6.92 | 6.88 | 2.17 |
Return on Equity (ROE) | 7.09% | 8.37% | 13.75% | 11.34% | 9.57% | 7.13% |
Return on Assets (ROA) | 3.62% | 4.72% | 6.87% | 5.86% | 3.86% | 3.67% |
Return on Invested Capital (ROIC) | 8.80% | 11.67% | 16.20% | 13.35% | 8.16% | 7.92% |
Return on Capital Employed (ROCE) | 6.30% | 7.60% | 12.30% | 9.90% | 6.80% | 6.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.47% | 3.10% | 3.25% | 3.39% | 3.95% | 3.10% |
FCF Yield | -0.92% | 0.43% | 3.15% | 4.90% | 4.66% | 2.21% |
Dividend Yield | 6.61% | - | 3.34% | 3.52% | 4.12% | 3.31% |
Payout Ratio | 183.52% | 144.06% | 69.90% | 74.93% | 66.21% | 57.57% |
Buyback Yield / Dilution | -3.28% | -3.33% | 2.58% | -2.39% | -5.18% | -0.61% |
Total Shareholder Return | 3.33% | -3.33% | 5.92% | 1.13% | -1.07% | 2.70% |